RecruitingNot ApplicableNCT07425080

HELIOS Advanced: Human Oocyte Illumination to Enhance Development

HELIOS-Advanced: A Prospective, Staged Dose-Escalation Study of Photobiomodulation to Improve Embryo Development in In Vitro Fertilization


Sponsor

Columbia University

Enrollment

270 participants

Start Date

Mar 24, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Oocytes need a lot of energy to complete meiosis and fertilize successfully. As women get older, the "power plants" of the cells (called mitochondria) don't work as well. This makes it harder for eggs and embryos to develop normally. One possible way to help is with a gentle light treatment called photobiomodulation (PBM). This uses a special type of red light that boosts energy production in cells and helps them stay healthy. This study will test whether adding this light treatment during in vitro fertilization (IVF) can improve embryo growth and pregnancy outcomes.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 48 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Photobiomodulation for people with ivf outcomes. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 48 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPhotobiomodulation

Photobiomodulation (PBM): also known as low-level light therapy (LLLT), involves the application of low-intensity red or near-infrared (NIR) light to modulate mitochondrial activity.


Locations(1)

Columbia University Fertility Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07425080


Related Trials